The fourth mammalian molybdenum enzyme mARC: current state of research

References

• Abbenante, G., Fairlie D. P. (2005). Protease inhibitors in the clinic. Med Chem 1:71–104.
   Google Scholar
• Aberg K., Adkins D. E., Bukszar J., Webb B. T., Caroff S. N., Miller del D., et al. (2010). Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:279–282.
   PubMed Web of Science ®Google Scholar
• Altuve A., Silchenko S., Lee K. H., Kuczera K., Terzyan S., Zhang X., et al. (2001). Probing the differences between rat liver outer mitochondrial membrane cytochrome b5 and microsomal cytochromes b5. Biochemistry 40:9469–9483.
   PubMed Web of Science ®Google Scholar
• Anantharaman, V., Aravind L. (2002). MOSC domains, ancient, predicted sulfur-carrier domains, present in diverse metal-sulfur cluster biosynthesis proteins including Molybdenum cofactor sulfurases. FEMS Microbiol Lett 207:55–61.
   PubMed Web of Science ®Google Scholar
• Andersson S., Hofmann Y., Nordling A., Li X. Q., Nivelius S., Andersson T. B., et al. (2005). Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos 33:570–578.
   PubMed Web of Science ®Google Scholar
• Ansede, J. H., Voyksner, R. D., Ismail, M. A., Boykin, D. W., Tidwell, R. R., Hall J. E. (2005). In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica 35:211–226.
   PubMed Web of Science ®Google Scholar
• Barbier, G. G., Joshi, R. C., Campbell, E. R., Campbell W. H. (2004). Purification and biochemical characterization of simplified eukaryotic nitrate reductase expressed in Pichia pastoris. Protein Expr Purif 37:61–71.
   PubMed Web of Science ®Google Scholar
• Barham, H. M., Stratford I. J. (1996). Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. Biochem Pharmacol 51:829–837.
   PubMed Web of Science ®Google Scholar
• Beedham C. (1985). Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16:119–156.
   PubMed Web of Science ®Google Scholar
• Beedham C. (1997). The role of non-P450 enzymes in drug oxidation. Pharm World Sci 19:255–263.
   PubMed Web of Science ®Google Scholar
• Bernardi, P., Azzone G. F. (1981). Cytochrome c as an electron shuttle between the outer and inner mitochondrial membranes. J Biol Chem 256:7187–7192.
   PubMed Web of Science ®Google Scholar
• Berndt, C., Lillig, C. H., Holmgren A. (2007). Thiol-based mechanisms of the thioredoxin and glutaredoxin systems, implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 292:H1227–H1236.
   PubMed Web of Science ®Google Scholar
• Bernheim M. L. (1969). The hydroxylamine reductase of mitochondria. Arch Biochem Biophys 134:408–413.
   PubMed Web of Science ®Google Scholar
• Bernheim M. L. (1972). The reduction of hydroxylamine and some aryl hydroxamates by liver mitochondria from mammals and birds. Enzymologia 43:167–176.
   PubMedGoogle Scholar
• Bernheim, M. L., Hochstein P. (1968). Reduction of hydroxylamine by rat liver mitochondria. Arch Biochem Biophys 124:436–442.
   PubMed Web of Science ®Google Scholar
• Bittner, F., Oreb, M., Mendel R. R. (2001). ABA3 is a molybdenum cofactor sulfurase required for activation of aldehyde oxidase and xanthine dehydrogenase in Arabidopsis thaliana. J Biol Chem 276:40381–40384.
   PubMed Web of Science ®Google Scholar
• Borgese, N., D’Arrigo, A., De Silvestris, M., Pietrini G. (1993). NADH-cytochrome b5 reductase and cytochrome b5 isoforms as models for the study of post-translational targeting to the endoplasmic reticulum. FEBS Lett 325:70–75.
   PubMed Web of Science ®Google Scholar
• Borgese, N., Gazzoni, I., Barberi, M., Colombo, S., Pedrazzini E. (2001). Targeting of a tail-anchored protein to endoplasmic reticulum and mitochondrial outer membrane by independent but competing pathways. Mol Biol Cell 12:2482–2496.
   PubMed Web of Science ®Google Scholar
• Bulbarelli, A., Valentini, A., DeSilvestris, M., Cappellini, M. D., Borgese N. (1998). An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans. Blood 92:310–319.
   PubMed Web of Science ®Google Scholar
• Burgess, B. K., Lowe D. J. (1996). Mechanism of molybdenum nitrogenase. Chem Rev 96:2983–2912.
   PubMed Web of Science ®Google Scholar
• Campbell W. H. (1999). Nitrate reductase structure, function, and regulation: bridging the gap between biochemistry and physiology. Annu Rev Plant Physiol Plant Mol Biol 50:277–303.
   PubMed Web of Science ®Google Scholar
• Chen X., Li X., Wang P., Liu Y., Zhang Z., Zhao G., et al. (2010). Novel association strategy with copy number variation for identifying new risk Loci of human diseases. PLoS One. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012185. Accessed on August 20, 2010.
   Google Scholar
• Clement B. (1993). Inventor. Methoden zur Behandlung und Prophylaxe der Pneumocystis carinii pneumonie (PCP) und anderen Erkrankungen sowie Verbindungen und Formulierungen zum Gebrauch bei besagten Methoden. German patent P 4321444.4, PCT/DE 94/00756 (1994); U.S. patent 5,786,383 (1998 July 28); European patent 0708640 (1998 September 16).
   Google Scholar
• Clement B. (2002). Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 34:565–579.
   PubMed Web of Science ®Google Scholar
• Clement, B., Behrens, D., Möller, W., Cashman J. R. (2000). Reduction of amphetamine hydroxylamine and other aliphatic hydroxylamines by benzamidoxime reductase and human liver microsomes. Chem Res Toxicol 13:1037–1045.
   PubMed Web of Science ®Google Scholar
• Clement, B., Bürenheide, A., Rieckert, W., Schwarz J.(2006). Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem 1:1260–1267.
   PubMed Web of Science ®Google Scholar
• Clement, B., Christiansen, K., Girreser U. (2001). Phase 2 metabolites of N-hydroxylated amidines (amidoximes): synthesis, in vitro formation by pig hepatocytes, and mutagenicity testing. Chem Res Toxicol 14:319–326.
   PubMed Web of Science ®Google Scholar
• Clement, B., Havemeyer, A., Krischkowski, C., Bittner, F., Mendel R. (2010). The newly discovered molybdenum-containing enzyme mARC is a novel extrahepatic drug metabolizing enzyme. Drug Metab Rev 42(Suppl 1):1–323.
   Google Scholar
• Clement, B., Immel, M., Terlinden, R., Wingen F. J. (1992). Reduction of amidoxime derivatives to pentamidine in vivo. Arch Pharm (Weinheim) 325:61–62.
   PubMed Web of Science ®Google Scholar
• Clement, B., Jung F. (1994). N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide. Drug Metab Dispos 22:486–497.
   PubMed Web of Science ®Google Scholar
• Clement, B., Kunze T. (1992). The reduction of 6-N-hydroxylaminopurine to adenine by xanthine oxidase. Biochem Pharmacol 44:1501–1509.
   PubMed Web of Science ®Google Scholar
• Clement, B., Lomb, R., Moller W. (1997). Isolation and characterization of the protein components of the liver microsomal O2-insensitive NADH-benzamidoxime reductase. J Biol Chem 272:19615–19620.
   PubMed Web of Science ®Google Scholar
• Clement, B., Lopian K. (2003). Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 31:645–651.
   PubMed Web of Science ®Google Scholar
• Clement, B., Mau, S., Deters, S., Havemeyer A. (2005). Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4- piperidinyl]oxy]-acetic acid). Drug Metab Dispos 33:1740–1747.
   PubMed Web of Science ®Google Scholar
• Clement, B., Raether W. (1985). Amidoximes of pentamidine, synthesis, trypanocidal, and leishmanicidal activity. Arzneimittelforschung 35:1009–1014.
   PubMed Web of Science ®Google Scholar
• Colombo S., Longhi R., Alcaro S., Ortuso F., Sprocati T., Flora A., et al. (2005). N-myristoylation determines dual targeting of mammalian NADH-cytochrome b5 reductase to ER and mitochondrial outer membranes by a mechanism of kinetic partitioning. J Cell Biol 168:735–745.
   PubMed Web of Science ®Google Scholar
• Cribb, A. E., Spielberg, S. P., Griffin G. P. (1995). N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406–414.
   PubMed Web of Science ®Google Scholar
• Da Cruz, S., Xenarios, I., Langridge, J., Vilbois, F., Parone, P. A., Martinou J. C. (2003). Proteomic analysis of the mouse liver mitochondrial inner membrane. J Biol Chem 278:41566–41571.
   PubMed Web of Science ®Google Scholar
• Dambrova, M., Uhlen, S., Welch, C. J., Wikberg J. E. (1998). Identification of an N-hydroxyguanidine reducing activity of xanthine oxidase. Eur J Biochem 257:178–184.
   PubMedGoogle Scholar
• D’Arrigo, A., Manera, E., Longhi, R., Borgese N. (1993). The specific subcellular localization of two isoforms of cytochrome b5 suggests novel targeting pathways. J Biol Chem 268:2802–2808.
   PubMed Web of Science ®Google Scholar
• Dick, R. A., Kanne, D. B., Casida JE. (2006). Substrate specificity of rabbit aldehyde oxidase for nitroguanidine and nitromethylene neonicotinoid insecticides. Chem Res Toxicol 19:38–43.
   PubMed Web of Science ®Google Scholar
• Dmitriev L. F. (2001). Activity of key enzymes in microsomal and mitochondrial membranes depends on the redox reactions involving lipid radicals. Membr Cell Biol 14:649–662.
   PubMedGoogle Scholar
• Dmitriev L. F. (2007). Shortage of lipid-radical cycles in membranes as a possible prime cause of energetic failure in aging and Alzheimer disease. Neurochem Res 32:1278–1291.
   PubMed Web of Science ®Google Scholar
• Ettmayer, P., Amidon, G. L., Clement, B., Testa B. (2004). Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393–2404.
   PubMed Web of Science ®Google Scholar
• Finn R. D., McLaughlin L. A., Ronseaux S., Rosewell I., Houston J. B., Henderson C. J., et al. (2008). Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J Biol Chem 283:31385–31393.
   PubMed Web of Science ®Google Scholar
• Fischer, K., Barbier, G. G. Hecht, H. J., Mendel, R. R., Campbell, W. H., Schwarz G. (2005). Structural basis of eukaryotic nitrate reduction: crystal structures of the nitrate reductase active site. Plant Cell 17:1167–1179.
   PubMed Web of Science ®Google Scholar
• Fischer K., Llamas A., Tejada-Jimenez M., Schrader N., Kuper J., Ataya F. S., et al. (2006). Function and structure of the molybdenum cofactor carrier protein from Chlamydomonas reinhardtii. J Biol Chem 281:30186–30194.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons, S. A., Lewis, A. D., Riley, R. J., Workman P. (1994). Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15:1503–1510.
   PubMed Web of Science ®Google Scholar
• Fuller A. T. (1947). Antibacterial action of some aromatic amines, amidines, amidoximes, guanidines, and diguanides. Biochem J 41:403–408.
   Web of Science ®Google Scholar
• Groebke Zbinden K., Banner D. W., Hilpert K., Himber J., Lave T., Riederer M. A., et al. (2006). Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity. Bioorg Med Chem 14:5357–5369.
   PubMed Web of Science ®Google Scholar
• Gruenewald S., Wahl B., Bittner F., Hungeling H., Kanzow S., Kotthaus J., et al. (2008). The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs. J Med Chem 51:8173–8177.
   PubMed Web of Science ®Google Scholar
• Gustafsson, D., Elg M. (2003). The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109(Suppl 1):9–15.
   Google Scholar
• Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., Gyzander E., et al. (2001). The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171–181.
   PubMed Web of Science ®Google Scholar
• Hall J. E., Kerrigan J. E., Ramachandran K., Bender B. C., Stanko J. P., Jones S. K., et al. (1998). Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother 42:666–674.
   PubMed Web of Science ®Google Scholar
• Harrison R. (2004). Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36:363–375.
   PubMed Web of Science ®Google Scholar
• Hauptmann, J., Paintz, M., Kaiser, B., Richter M. (1988). Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro. Pharmazie 43:559–560.
   PubMed Web of Science ®Google Scholar
• Havemeyer, A., Bittner, F., Wollers, S., Mendel, R., Kunze, T., Clement B. (2006). Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. J Biol Chem 281:34796–34802.
   PubMed Web of Science ®Google Scholar
• Havemeyer A., Grunewald S., Wahl B., Bittner F., Mendel R., Erdelyi P., et al. (2010). Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC. Drug Metab Dispos 38:1917–1921.
   PubMed Web of Science ®Google Scholar
• Heidenreich, T., Wollers, S., Mendel, R. R., Bittner F. (2005). Characterization of the NifS-like domain of ABA3 from Arabidopsis thaliana provides insight into the mechanism of molybdenum cofactor sulfuration. J Biol Chem 280:4213–4218.
   PubMed Web of Science ®Google Scholar
• Higuchi, S., Matsushita, S., Murayama, M., Takagi, S., Hayashida M. (1995). Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry 152;1219–1221.
   PubMed Web of Science ®Google Scholar
• Hille R. (1996). The mononuclear molybdenum enzymes. Chem Rev 96:2757–2816.
   PubMed Web of Science ®Google Scholar
• Hille, R., Nishino, T., Bittner F. (2011). Molybdenum enzymes in higher organism. Coord Chem Rev 255:1179–1205.
   PubMed Web of Science ®Google Scholar
• Hipkin, C. R., Kau, D. A., Cannons A. C. (1993). Further characterization of the assimilatory nitrate reductase from the yeast Candida nitratophila. J Gen Microbiol 139:473–478.
   PubMedGoogle Scholar
• Hirsch, P. F., Kaplan N. O. (1961). The conversion of pyridine hydroxamic acids to amides by mouse liver mitochondria. J Biol Chem 236:926–930.
   PubMed Web of Science ®Google Scholar
• Huang T. L., Bacchi C. J., Kode N. R., Zhang Q., Wang G., Yartlet N., et al. (2007). Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int J Antimicrob Agents 30:555–561.
   PubMed Web of Science ®Google Scholar
• Ichida, K., Matsumura, T., Sakuma, R., Hosoya, T., Nishino T. (2001). Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun 282:1194–1200.
   PubMed Web of Science ®Google Scholar
• Islinger, M., Luers, G. H., Li, K. W., Loos, M., Volkl A. (2007). Rat liver peroxisomes after fibrate treatment. A survey using quantitative mass spectrometry. J Biol Chem 282:23055–23069.
   PubMed Web of Science ®Google Scholar
• Ito A. (1980). Cytochrome b5-like hemoprotein of outer mitochondrial membrane; OM cytochrome b. I. Purification of OM cytochrome b from rat liver mitochondria and comparison of its molecular properties with those of cytochrome b5. J Biochem (Tokyo) 87:63–71.
   Google Scholar
• Ito, A., Hayashi, S., Yoshida T. (1981). Participation of a cytochrome b5-like hemoprotein of outer mitochondrial membrane (OM cytochrome b) in NADH-semidehydroascorbic acid reductase activity of rat liver. Biochem Biophys Res Commun 101:591–598.
   PubMed Web of Science ®Google Scholar
• Iyanagi, T., Watanabe, S., Anan K. F. (1984). One-electron oxidation-reduction properties of hepatic NADH-cytochrome b5 reductase. Biochemistry 23:1418–1425.
   PubMed Web of Science ®Google Scholar
• Jana, S., Mandlekar, S., Marathe P. (2010). Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem 17:3874–3908.
   PubMed Web of Science ®Google Scholar
• Johansson, L. C., Andersson, M., Fager, G., Gustafsson, D., Eriksson U. G. (2003). No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 42:475–484.
   PubMed Web of Science ®Google Scholar
• Josephy, P. D., Palcic, B., Skarsgard L. D. (1981). Reduction of misonidazole and its derivatives by xanthine oxidase. Biochem Pharmacol 30:849–853.
   PubMed Web of Science ®Google Scholar
• Kadlubar, F. F., Ziegler D. M. (1974). Properties of a NADH-dependent N-hydroxy amine reductase isolated from pig liver microsomes. Arch Biochem Biophys 162:83–92.
   PubMed Web of Science ®Google Scholar
• Kadlubar, F. F., McKee, E. M., Ziegler D. M. (1973). Reduced pyridine nucleotide-dependent N-hydroxy amine oxidase and reductase activities of hepatic microsomes. Arch Biochem Biophys 156:46–57.
   PubMed Web of Science ®Google Scholar
• Keisu, M., Andersson T. B. (2010). Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 196:407–418.
   PubMedGoogle Scholar
• Ketchum, P. A., Cambier, H. Y., Frazier W. A., 3rd, Madansky C. H., Nason A. (1970). In vitro assembly of Neurospora assimilatory nitrate reductase from protein subunits of a Neurospora mutant and the xanthine oxidizing or aldehyde oxidase systems of higher animals. Proc Natl Acad Sci U S A 66:1016–1023.
   PubMed Web of Science ®Google Scholar
• Kimura, S., Kawamura, M., Iyanagi T. (2003). Role of Thr(66) in porcine NADH-cytochrome b5 reductase in catalysis and control of the rate-limiting step in electron transfer. J Biol Chem 278:3580–3589.
   PubMed Web of Science ®Google Scholar
• Kindmark A., Jawaid A., Harbron C. G., Barratt B. J., Bengtsson O. F., Andersson T. B., et al. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186–195.
   PubMed Web of Science ®Google Scholar
• Kitamura, S., Tatsumi K. (1983). Azoreductase activity of liver aldehyde oxidase. Chem Pharm Bull (Tokyo) 31:3334–3337.
   PubMed Web of Science ®Google Scholar
• Kitamura, S., Sugihara, K., Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83–98.
   PubMed Web of Science ®Google Scholar
• Kitamura, S., Sugihara, K., Tatsumi K. (1994). Reductase activity of aldehyde oxidase toward the carcinogen N-hydroxy-2-acetylaminofluorene and the related hydroxamic acids. Biochem Mol Biol Int 34:1197–1203.
   PubMedGoogle Scholar
• Kotthaus J., Wahl B., Havemeyer A., Kotthaus J., Schade D., Garbe-Schonberg D., et al. (2010). Reduction of N(omega)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC). Biochem J 433:383–391.
   Web of Science ®Google Scholar
• Kozmin, S. G., Leroy, P., Pavlov, Y. I., Schaaper R. M. (2008). YcbX and yiiM, two novel determinants for resistance of Escherichia coli to N-hydroxylated base analogues. Mol Microbiol 68:51–65.
   PubMed Web of Science ®Google Scholar
• Kozmin, S. G., Wang, J., Schaaper R. M. (2010). Role for CysJ flavin reductase in molybdenum cofactor-dependent resistance of Escherichia coli to 6-N-hydroxylaminopurine. J Bacteriol 192:2026–2033.
   PubMed Web of Science ®Google Scholar
• Kurian, J. R., Bajad, S. U., Miller, J. L., Chin, N. A., Trepanier L. A. (2004). NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 311:1171–1178.
   PubMed Web of Science ®Google Scholar
• Kurian, J. R., Chin, N. A., Longlais, B. J., Hayes, K. L., Trepanier L. A. (2006). Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Chem Res Toxicol 19:1366–1373.
   PubMed Web of Science ®Google Scholar
• Lederer, F., Ghrir, R., Guiard, B., Cortial, S., Ito A. (1983). Two homologous cytochromes b5 in a single cell. Eur J Biochem 132:95–102.
   PubMedGoogle Scholar
• Lee, K. H., Kuczera K. (2003). Molecular dynamics simulation studies of cytochrome b5 from outer mitochondrial and microsomal membrane. Biopolymers 69:260–269.
   PubMed Web of Science ®Google Scholar
• Leroux, A., Mota Vieira, L., Kahn A. (2001). Transcriptional and translational mechanisms of cytochrome b5 reductase isoenzyme generation in humans. Biochem J 355:529–535.
   PubMed Web of Science ®Google Scholar
• Liederer, B. M., Borchardt R. T. (2006). Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95:1177–1195.
   PubMed Web of Science ®Google Scholar
• Lip G. Y., Rasmussen L. H., Olsson S. B., Jensen E. C., Persson A. L., Eriksson U., et al. (2009). Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 30:2897–2907.
   PubMed Web of Science ®Google Scholar
• Malik, A. N., Rossios, C., Al-Kafaji, G., Shah, A., Page R. A. (2007). Glucose regulation of CDK7, a putative thiol related gene, in experimental diabetic nephropathy. Biochem Biophys Res Commun 357:237–244.
   PubMed Web of Science ®Google Scholar
• Matsson E. M., Palm J. E., Eriksson U. G., Bottner P., Lundahl A., Knutson L., et al. (2010). Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs. Drug Metab Dispos 39:239–246.
   PubMed Web of Science ®Google Scholar
• Mehrotra, M. M., Heath, J. A., Smyth, M. S., Pandey, A., Rose, J. W., Seroogy J. M., et al. (2004). Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists. J Med Chem 47:2037–2061.
   PubMed Web of Science ®Google Scholar
• Mendel, R. R., Bittner F. (2006). Cell biology of molybdenum. Biochim Biophys Acta 1763:621–635.
   PubMed Web of Science ®Google Scholar
• Meyer J. E., Brocks C., Graefe H., Mala C., Thans N., Burgle M., et al. (2008). The oral serine protease inhibitor WX-671—first experience in patients with advanced head and neck carcinoma. Breast Care (Basel) 3:20–24.
   PubMed Web of Science ®Google Scholar
• Mikula, M., Rubel, T., Karczmarski, J., Goryca, K., Dadlez, M., Ostrowski J. (2011). Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics 11:215–224.
   PubMed Web of Science ®Google Scholar
• Mitani, F., Ogishima, T., Mukai, K., Hoshino, R., Watanabe, K., Suematsu M. (2004). Possible participation of outer mitochondrial membrane cytonchrome B5 in steroidogenesis in zona glomerulosa of rat adrenal cortex. Endocr Res 30:639–644.
   PubMed Web of Science ®Google Scholar
• Molavi A. (1989). Pentamidine for the prevention and treatment of P. carinii pneumonia. Am Fam Physician 40:195–200.
   PubMed Web of Science ®Google Scholar
• Mootha V. K., Bunkenborg J., Olsen J. V., Hjerrild M., Wisniewski J. R., Stahl E., et al. (2003). Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 115:629–640.
   PubMed Web of Science ®Google Scholar
• Mota Vieira, L., Kaplan, J. C., Kahn, A., Leroux A. (1994). Heterogeneity of the rat NADH-cytochrome-b5-reductase transcripts resulting from multiple alternative first exons. Eur J Biochem 220:729–737.
   PubMedGoogle Scholar
• Murray, K. N., Chaykin S. (1966). The reduction of nicotinamide N-oxide by xanthine oxidase. J Biol Chem 241:3468–3473.
   PubMed Web of Science ®Google Scholar
• Nason, A., Lee, K. Y., Pan, S. S., Ketchum, P. A., Lamberti, A., DeVries J. (1971). In vitro formation of assimilatory reduced nicotinamide adenine dinucleotide phosphate: nitrate reductase from a Neurospora mutant and a component of molybdenum-enzymes. Proc Natl Acad Sci U S A 68:3242–3246.
   PubMed Web of Science ®Google Scholar
• Nishida, C. R., Lee, M., de Montellano P. R. (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78:497–502.
   PubMed Web of Science ®Google Scholar
• Nishino, H., Ito A. (1986). Subcellular distribution of OM cytochrome b-mediated NADH-semidehydroascorbate reductase activity in rat liver. J Biochem 100:1523–1531.
   PubMed Web of Science ®Google Scholar
• Ogishima, T., Kinoshita, J. Y., Mitani, F., Suematsu, M., Ito A. (2003). Identification of outer mitochondrial membrane cytochrome b5 as a modulator for androgen synthesis in Leydig cells. J Biol Chem 278:21204–21211.
   PubMed Web of Science ®Google Scholar
• Ouattara, M., Wein, S., Calas, M., Hoang, Y. V., Vial, H., Escale R. (2007). Synthesis and antimalarial activity of new 1,12-bis(N,N’-acetamidinyl)dodecane derivatives. Bioorg Med Chem Lett 17:593–596.
   PubMed Web of Science ®Google Scholar
• Ouattara M., Wein S., Denoyelle S., Ortial S., Durand T., Escale R., et al. (2009). Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents. Bioorg Med Chem Lett 19:624–626.
   PubMed Web of Science ®Google Scholar
• Ozols, J., Carr, S. A., Strittmatter P. (1984). Identification of the NH2-terminal blocking group of NADH-cytochrome b5 reductase as myristic acid and the complete amino acid sequence of the membrane-binding domain. J Biol Chem 259:13349–13354.
   PubMedGoogle Scholar
• Page, R., Morris, C., Williams, J., von Ruhland, C., Malik A. N. (1997). Isolation of diabetes-associated kidney genes using differential display. Biochem Biophys Res Commun 232:49–53.
   PubMed Web of Science ®Google Scholar
• Pagliarini D. J., Calvo S. E., Chang B., Sheth S. A., Vafai S. B., Ong S. E., et al. (2008). A mitochondrial protein compendium elucidates complex I disease biology. Cell 134:112–123.
   PubMed Web of Science ®Google Scholar
• Panoutsopoulos, G. I., Beedham C. (2004). Kinetics and specificity of guinea pig liver aldehyde oxidase and bovine milk xanthine oxidase towards substituted benzaldehydes. Acta Biochim Pol 51:649–663.
   PubMed Web of Science ®Google Scholar
• Passon, P. G., Hultquist D. E. (1972). Soluble cytochrome b5 reductase from human erythrocytes. Biochim Biophys Acta 275:62–73.
   PubMed Web of Science ®Google Scholar
• Patrick D. A., Hall J. E., Bender B. C., McCurdy D. R., Wilson W. D., Tanious F. A., et al. (1999). Synthesis and anti-Pneumocystis carinii pneumonia activity of novel dicationic dibenzothiophenes and orally active prodrugs. Eur J Med Chem 34:575–583.
   PubMed Web of Science ®Google Scholar
• Peterlin-Masic, L., Cesar, J., Zega A. (2006). Metabolism-directed optimisation of antithrombotics: the prodrug principle. Curr Pharm Des 12:73–91.
   PubMed Web of Science ®Google Scholar
• Pienkos, P. T., Shah, V. K., Brill W. J. (1977). Molybdenum cofactors from molybdoenzymes and in vitro reconstitution of nitrogenase and nitrate reductase. Proc Natl Acad Sci U S A 74:5468–5471.
   PubMed Web of Science ®Google Scholar
• Porter T. D. (2002). The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 16:311–316.
   PubMed Web of Science ®Google Scholar
• Powis, G., Wincentsen L. (1980). Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450. Biochem Pharmacol 29:347–351.
   PubMed Web of Science ®Google Scholar
• Pryde, D. C., Dalvie, D., Hu, Q., Jones, P., Obach, R. S., Tran T. D. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–8460.
   PubMed Web of Science ®Google Scholar
• Rahmathullah, S. M., Hall, J. E., Bender, B. C., McCurdy, D. R., Tidwell, R. R., Boykin D. W. (1999). Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan. J Med Chem 42:3994–4000.
   PubMed Web of Science ®Google Scholar
• Rajagopalan, K. V., Johnson J. L. (1992). The pterin molybdenum cofactors. J Biol Chem 267:10199–10202.
   PubMed Web of Science ®Google Scholar
• Rapaport D. (2003). Finding the right organelle. Targeting signals in mitochondrial outer-membrane proteins. EMBO Rep 4:948–952.
   PubMed Web of Science ®Google Scholar
• Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., et al. (2008). Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255–270.
   PubMed Web of Science ®Google Scholar
• Riggs J. R., Kolesnikov A., Hendrix J., Young W. B., Shrader W. D., Vijaykumar D., et al. (2006). Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability. Bioorg Med Chem Lett 16:2224–2228.
   PubMed Web of Science ®Google Scholar
• Rivera, M., Barillas-Mury, C., Christensen, K. A., Little, J. W., Wells, M. A., Walker F. A. (1992). Gene synthesis, bacterial expression, and 1H NMR spectroscopic studies of the rat outer mitochondrial membrane cytochrome b5. Biochemistry 31:12233–12240.
   PubMed Web of Science ®Google Scholar
• Rivera, M., Wells, M. A., Walker F. A. (1994). Cation-promoted cyclic voltammetry of recombinant rat outer mitochondrial membrane cytochrome b5 at a gold electrode modified with beta-mercaptopropionic acid. Biochemistry 33:2161–2170.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Maranon M. J., Qiu F., Stark R. E., White S. P., Zhang X., Foundling S. I., et al. (1996). 13C NMR spectroscopic and X-ray crystallographic study of the role played by mitochondrial cytochrome b5 heme propionates in the electrostatic binding to cytochrome c. Biochemistry 35:16378–16390.
   PubMed Web of Science ®Google Scholar
• Romao M. J. (2009). Molybdenum and tungsten enzymes: a crystallographic and mechanistic overview. Dalton Trans 41:4053–4068.
   Google Scholar
• Saido H., Watanabe F., Tamura Y., Miyatake K., Ito A., Yubisui T., et al. (1994). Cytochrome b5-like hemoprotein/cytochrome b5 reductase complex in rat liver mitochondria has NADH-linked aquacobalamin reductase activity. J Nutr 124:1037–1040.
   PubMed Web of Science ®Google Scholar
• Salom-Roig, X. J., Hamze, A., Calas, M., Vial H. J. (2005). Dual molecules as new antimalarials. Comb Chem High Throughput Screen 8:49–62.
   PubMed Web of Science ®Google Scholar
• Saulter J. Y., Kurian J. R., Trepanier L. A., Tidwell R. R., Bridges A. S., Boykin D. W., et al. (2005). Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab Dispos 33:1886–1893.
   PubMed Web of Science ®Google Scholar
• Shirabe, K., Landi, M. T., Takeshita, M., Uziel, G., Fedrizzi, E., Borgese N. (1995). A novel point mutation in a 3’ splice site of the NADH-cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. Am J Hum Genet 57:302–310.
   PubMed Web of Science ®Google Scholar
• Shirk, R. A., Vlasuk G. P. (2007). Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 27:1895–1900.
   PubMed Web of Science ®Google Scholar
• Skalova, L., Nobilis, M., Szotakova, B., Wsol, V., Kvasnickova E. (1998). Induction and inhibition of cytochrome P450-catalysed reduction of biologically active benfluron N-oxide. Drug Metabol Drug Interact 14:221–233.
   PubMedGoogle Scholar
• Slaughter, S. R., Williams, C. H., Hultquist D. E. (1982). Demonstration that bovine erythrocyte cytochrome b5 is the hydrophilic segment of liver microsomal cytochrome b5. Biochim Biophys Acta 705:228–237.
   PubMed Web of Science ®Google Scholar
• Soeiro, M. N., de Castro, S. L., de Souza, E. M., Batista, D. G., Silva, C. F., Boykin D. W. (2008). Diamidine activity against trypanosomes: the state of the art. Curr Mol Pharmacol 1:151–161.
   PubMedGoogle Scholar
• Song Y., Clizbe L., Bhakta C., Teng W., Wong P., Huang B., et al. (2003). Design and synthesis of factor Xa inhibitors and their prodrugs. Bioorg Med Chem Lett 13:297–300.
   PubMed Web of Science ®Google Scholar
• Squizzato, A., Dentali, F., Steidl, L., Ageno W. (2009). New direct thrombin inhibitors. Intern Emerg Med 4:479–484.
   PubMed Web of Science ®Google Scholar
• Stoddart, A. M., Levine W. G. (1992). Azoreductase activity by purified rabbit liver aldehyde oxidase. Biochem Pharmacol 43:2227–2235.
   PubMed Web of Science ®Google Scholar
• Stöhrer G. (1968). Reduction of hydroxylamine derivates by xanthine oxidase. Israel J Chem 6:845–846.
   Web of Science ®Google Scholar
• Strittmatter, P., Hackett, C. S., Korza, G., Ozols J. (1990). Characterization of the covalent cross-links of the active sites of amidinated cytochrome b5 and NADH:cytochrome b5 reductase. J Biol Chem 265:21709–21713.
   PubMed Web of Science ®Google Scholar
• Strittmatter, P., Spatz, L., Corcoran, D., Rogers, M. J., Setlow, B., Redline R. (1974). Purification and properties of rat liver microsomal stearyl coenzyme A desaturase. Proc Natl Acad Sci U S A 71:4565–4569.
   PubMed Web of Science ®Google Scholar
• Su A. I., Wiltshire T., Batalov S., Lapp H., Ching K. A., Block D., et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptones. PNAS 101:6062–6067.
   PubMed Web of Science ®Google Scholar
• Sugihara, K., Tatsumi K. (1986). Participation of liver aldehyde oxidase in reductive metabolism of hydroxamic acids to amides. Arch Biochem Biophys 247:289–293.
   PubMed Web of Science ®Google Scholar
• Sugiura, M., Iwasaki, K., Kato R. (1977). Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P-450. Biochem Pharmacol 26:489–495.
   PubMed Web of Science ®Google Scholar
• Takekawa, K., Sugihara, K., Kitamura, S., Ohta S. (2001). Enzymatic and non-enzymatic reduction of brucine N-oxide by aldehyde oxidase and catalase. Xenobiotica 31:769–782.
   PubMed Web of Science ®Google Scholar
• Tan W. H., Eichler F. S., Hoda S., Lee M. S., Baris H., Hanley C. A., et al. (2005). Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature. Pediatrics 116:757–766.
   PubMed Web of Science ®Google Scholar
• Tatsumi, K., Ishigai M. (1987). Oxime-metabolizing activity of liver aldehyde oxidase. Arch Biochem Biophys 253:413–418.
   PubMed Web of Science ®Google Scholar
• Tatsumi, K., Inoue, A., Yoshimura H. (1981). Mode of reactions between xanthine oxidase and aromatic nitro compounds. J Pharmacobiodyn 4:101–108.
   PubMedGoogle Scholar
• Tatsumi, K., Yamada, H., Kitamura S. (1983a). Reductive metabolism of N-nitrosodiphenylamine to the corresponding hydrazine derivative. Arch Biochem Biophys 226:174–181.
   PubMed Web of Science ®Google Scholar
• Tatsumi, K., Yamada, H., Kitamura S. (1983b). Evidence for involvement of liver aldehyde oxidase in reduction of nitrosamines to the corresponding hydrazine. Chem Pharm Bull (Tokyo) 31:764–767.
   PubMed Web of Science ®Google Scholar
• Teslovich T. M., Musunuru K., Smith A. V., Edmondson A. C., Stylianou I. M., Koseki M, et al. (2010). Biological, clinical, and population relevance of 95 loci for blood lipids. Nature 466:707–713.
   PubMed Web of Science ®Google Scholar
• Tilley, J. W. (2007). Prodrugs of benzamidines. In: Stella V. J., Borchardt R. T., Hegeman M. J., Oliyai R., Maag H., Tilley J. W. (Eds.), Prodrugs: challenges and rewards. Part 2 ( pp. 190–222). New York: Springer Science.
   Google Scholar
• Truong, H. N., Meyer, C., Daniel-Vedele F. (1991). Characteristics of Nicotiana tabacum nitrate reductase protein produced in Saccharomyces cerevisiae. Biochem J 278:393–397.
   PubMed Web of Science ®Google Scholar
• Uchida M., Okazaki K., Mukaiyama H., Isawa H., Kobayashi H., Shiohara H., et al. (2008). Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy. Bioorg Med Chem Lett 18:4682–4687.
   PubMed Web of Science ®Google Scholar
• Ueda, O., Sugihara, K., Ohta, S., Kitamura S. (2005). Involvement of molybdenum hydroxylases in reductive metabolism of nitro polycyclic aromatic hydrocarbons in mammalian skin. Drug Metab Dispos 33:1312–1318.
   PubMed Web of Science ®Google Scholar
• Uhl G. R., Drgon T., Lin Q., Johnson C., Walther D., Komiyama T., et al. (2008). Genome-wide association for methampetamine dependence. Arch Gen Psychiatry 65:345–355.
   PubMed Web of Science ®Google Scholar
• Vergères, G., Waskell L. (1995). Cytochrome b5: its functions, structure, and membrane topology. Biochimie 77:604–620.
   PubMed Web of Science ®Google Scholar
• Wahl B., Reichmann D., Niks D., Krompholz N., Havemeyer A., Clement B., et al. (2010). Biochemical and spectroscopic characterization of the human mitochondrial amidoxime reducing components human mARC-1 and human mARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes. J Biol Chem 285:37847–37859.
   PubMed Web of Science ®Google Scholar
• Walton, M. I., Wolf, C. R., Workman P. (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44:251–259.
   PubMed Web of Science ®Google Scholar
• Wang, L., Cowley, A. B., Benson D. R. (2007). Enhancing the thermal stability of mitochondrial cytochrome b5 by introducing a structural motif characteristic of the less stable microsomal isoform. Protein Eng Des Sel 20:511–520.
   PubMed Web of Science ®Google Scholar
• Wang M. Z., Saulter J. Y., Usuki E., Cheung Y. L., Hall M., Bridges A. S., et al. (2006). CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 34:1985–1994.
   PubMed Web of Science ®Google Scholar
• Watanabe, F., Nakano Y. (1997). Purification and characterization of aquacobalamin reductases from mammals. Methods Enzymol 281:295–305.
   PubMed Web of Science ®Google Scholar
• Weller T., Alig L., Beresini M., Blackburn B., Bunting S., Hadvary P., et al. (1996). Orally active fibrinogen receptor antagonists 2. Amidoximes as prodrugs of amidines. J Med Chem 39:3139–3147.
   PubMed Web of Science ®Google Scholar
• Wen, B., Coe, K. J., Rademacher, P., Fitch, W. L., Monshouwer, M., Nelson S. D. (2008). Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase. Chem Res Toxicol 21:2393–2406
   PubMed Web of Science ®Google Scholar
• Wenzler, T., Boykin, D. W., Ismail, M. A., Hall, J. E., Tidwell, R. R., Brun R. (2009). New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother 53:4185–4192.
   PubMed Web of Science ®Google Scholar
• Werbovetz K. (2006). Diamidines as antitrypanosomal, antileishmanial, and antimalarial agents. Curr Opin Investig Drugs 7:147–157.
   PubMed Web of Science ®Google Scholar
• Wiese S., Gronemeyer T., Ofman R., Kunze M., Grou C. P., Almeida J. A., et al. (2007). Proteomics characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling. Mol Cell Proteomics 6:2045–2057.
   PubMed Web of Science ®Google Scholar
• Wittke, B., Mackie, I. J., Machin, S. J., Timm, U., Zell, M., Goggin T. (1999). Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br J Clin Pharmacol 47:521–530.
   PubMed Web of Science ®Google Scholar
• Wollers S., Heidenreich T., Zarepour M., Zachmann D., Kraft C., Zhao Y., et al. (2008). Binding of sulfurated molybdenum cofactor to the C-terminal domain of ABA3 from Arabidopsis thaliana provides insight into the mechanism of molybdenum cofactor sulfuration. J Biol Chem 283:9642–9650.
   PubMed Web of Science ®Google Scholar
• Yamada, H., Baba, T., Oguri, K., Yoshimura H. (1988). Enzymic reduction of N-hydroxyamphetamine: the role of electron transfer system containing cytochrome b5. Biochem Pharmacol 37:368–370.
   PubMed Web of Science ®Google Scholar
• Yubisui, T., Murakami, K., Takeshita, M., Takano T. (1988). Purification by hydrophobic chromatography of soluble cytochrome b5 of human erythrocytes. Biochim Biophys Acta 936:447–451.
   PubMed Web of Science ®Google Scholar
• Zega, A., Mlinsek, G., Solmajer, T., Trampus-Bakija, A., Stegnar, M., Urleb U. (2004). Thrombin inhibitors built on an azaphenylalanine scaffold. Bioorg Med Chem Lett 14:1563–1667.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Gladyshev V. N. (2008). Molybdoproteomes and evolution of molybdenum utilization. J Mol Biol 379:881–899.
   PubMed Web of Science ®Google Scholar